1. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156
2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997.) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
3. Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C (2004) Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 16:265–274
4. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, et al. (2005) Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Gastrointestinal Cancers Symposium abstr 77
5. Kondo S, Ueno H, Okusaka T, Ikeda M, Morizane C, Najima M (2006) Gemcitabine monotherapy versus chemoradiotherapy using 5-FU in patients with locally advanced pancreatic cancer. 2006 Gastrointestinal Cancers Symposium, ASCO Abstr 137